Adagio Medical initiated with a Buy at Lake Street

Lake Street initiated coverage of Adagio Medical (ADGM) with a Buy rating and $4 price target Adagio, which recently released top-line pivotal clinical data for its ultra-low temperature cryoablation vCLAS catheter for the “underserved” ventricular tachycardia ablation market, is approaching several “important value-creating catalysts,” including the full FULCRUM-VT clinical data release due in the first half of 2026 and FDA approval that the firm expects in the second half of 2026, the analyst tells investors.